Press Releases

Press Releases

Press Releases

Date Title and Summary Additional Formats
May 26, 2016
Genomic Health Announces Presentation of Seven Oncotype DX® Studies at the 2016 American Society of Clinical Oncology Annual Meeting, Including Additional Prospective Outcomes Analysis
Presentations in Breast and Prostate Cancers Underscore Genomic Health's Industry-leading Commitment to Help Physicians and Patients Optimize Cancer Treatment Decisions
May 25, 2016
Genomic Health Announces Publication in Journal of Clinical Oncology Demonstrating Oncotype DX® Predicts Late Distant Recurrence in Breast Cancer
Findings Confirm that Oncotype DX May Help Identify Breast Cancer Patients with Greatest Potential to Benefit from Extended Hormonal Therapy
May 04, 2016
Genomic Health Reports Double-Digit Revenue and Test Growth in Announcement of First Quarter 2016 Financial Results
19% Increase in Revenue; 16% Increase in Tests Delivered
Unparalleled Prospective Outcomes Evidence Drives Further Growth in U.S. Invasive Breast Business; 16% Increase in Revenue and 11% Increase in Test Volume
Conference Call Today at 4:30 p.m. ET
May 03, 2016
Genomic Health to Present at Bank of America Merrill Lynch 2016 Health Care Conference
REDWOOD CITY, Calif. , May 3, 2016 /PRNewswire/ --  Genomic Health, Inc. (Nasdaq: GHDX) today announced that Kim Popovits , Chairman of the Board, Chief Executive Officer and President, will present at the Bank of America Merrill Lynch 2016 Health Care Conference at the Encore at Wynn Las Vegas on
Apr 27, 2016
Genomic Health to Announce First Quarter 2016 Financial Results and Host Conference Call on Wednesday, May 4, 2016
REDWOOD CITY, Calif. , April 27, 2016 /PRNewswire/ --  Genomic Health, Inc.  (Nasdaq: GHDX) today announced that the company will host a conference call and webcast on Wednesday, May 4 at 4:30 p.m. Eastern Time to discuss its first quarter 2016 financial results.  The call and webcast will follow
Mar 11, 2016
Genomic Health Announces Five-year Outcomes from International 'PlanB' Study Demonstrating the Clinical Utility of Oncotype DX® in Node-positive and High-risk Node-negative Breast Cancer
One of the Largest Contemporary Adjuvant Breast Cancer Trials in Europe Shows that Patients with Low Oncotype DX® Scores Can Be Spared Chemotherapy Even When Traditional Factors Indicate Higher-Risk Disease
Mar 09, 2016
German National Cancer Guidelines Distinguish Oncotype DX® as First and Only Multi-gene Breast Cancer Test with 1A Level of Evidence
Updated Guidelines Elevate Evidence following Publication of Multiple Large Prospective Outcomes Studies
Mar 02, 2016
Genomic Health to Present at the Cowen and Company 36th Annual Health Care Conference
REDWOOD CITY, Calif. , March 2, 2016 /PRNewswire/ --  Genomic Health, Inc. (Nasdaq: GHDX) today announced that Brad Cole , Chief Operating Officer and Chief Financial Officer, will present at the Cowen and Company 36 th Annual Health Care Conference at the Marriot Copley Place in Boston on
Mar 01, 2016
Journal of Clinical Oncology Publishes Prospective Outcomes Results from Large International Trial Using Oncotype DX®
New Publication of Results from 'PlanB' Study Reinforces Unique Value of Oncotype DX, the Only Multi-gene Breast Cancer Test with Prospective Outcomes Evidence in More Than 50,000 Patients
Five-year Results Accepted for Oral Presentation at European Breast Cancer Conference, Included in Official Congress Press Program
Feb 10, 2016
Genomic Health Announces 2016 Financial Outlook and Provides 2015 Fourth Quarter and Year-End Financial Results
Expects to Deliver Double-Digit Test and Revenue Growth in 2016
Plans to Launch First Liquid Biopsy Test Mid-2016
Conference Call Today at 4:30 p.m. ET